Barclays analyst Benjamin Budish raised the firm’s price target on Carlyle to $39 from $37 and keeps an Overweight rating on the shares. The analyst sees “green shoots emerging” for the alternative asset managers. Companies continue to see “green shoots,” but for Q3, the story is little changed versus Q2, the analyst tells investors in a research note. The firm expects inflows to be strongest at Ares and Apollo.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CG:
- Carlyle price target lowered to $30 from $31 at BofA
- Wolfe Research initiates the Alternative Asset Managers at Market Overweight
- Carlyle initiated with a Peer Perform at Wolfe Research
- Acentra Health awarded $52.3M contract from U.S. VA
- Carlyle in talks to acquire two Medtronic units for over $7B, Reuters says